Stifel Reiterates Buy Rating on Ascendis Pharma (ASND) as Yuviwel Approved for Achondroplasia
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $325.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
